No Data
No Data
Express News | Q32 Bio Announces Late-Breaking Presentation of Results From Signal-Aa Part a Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting
Q32 Bio Announces Late-Breaking Presentation of Results From SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting
Q32 Bio to Participate in Upcoming March Investor Conferences
Cautious Optimism: Q32 Bio's Strategic Shift to Focus on Bempikibart for Alopecia Areata
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Q32 Bio (QTTB) and Vaxcyte (PCVX)
Q32 Downgraded to Market Perform by BMO Over ADX-097
Unlock the Full List